Tel: 82-53-420-5536; Fax: (011) 82-53-427-1468
Promoter methylation of the RGC32 gene in nonsmall cell lung cancer
Version of Record online: 22 SEP 2010
Copyright © 2010 American Cancer Society
Volume 117, Issue 3, pages 590–596, 1 February 2011
How to Cite
Kim, D. S., Lee, J. Y., Lee, S. M., Choi, J. E., Cho, S. and Park, J. Y. (2011), Promoter methylation of the RGC32 gene in nonsmall cell lung cancer. Cancer, 117: 590–596. doi: 10.1002/cncr.25451
- Issue online: 20 JAN 2011
- Version of Record online: 22 SEP 2010
- Manuscript Revised: 16 APR 2010
- Manuscript Accepted: 16 APR 2010
- Manuscript Received: 11 MAR 2010
- overall survival
Lung cancer is the leading cause of cancer-related deaths worldwide. Epigenetic inactivation of certain genes by aberrant promoter methylation is recognized as a crucial component in the initiation and progression of lung cancer. Response gene to complement 32 (RGC32) has been identified as a cell cycle regulator induced by activation of complements; however, its role in carcinogenesis is still controversial.
The authors examined the methylation status in the promoter region of RGC32 gene in nonsmall cell lung cancers (NSCLCs) using a methylation-specific PCR and correlated the results with clinicopathological features.
RGC32 methylation was found in 45 of 173 NSCLCs (26.0%) and was related to the gene expression. RGC32 methylation was more frequent in females than in males (P<0.05). RGC32 methylation was not significantly associated with the prognosis of patients; however, when the patients were categorized by TP53 mutational status, the effect of RGC32 methylation on prognosis was significantly different between those with and without TP53 mutations (P = .005 [test for homogeneity]). Specifically, RGC32 methylation was associated with significantly worse survival in the cases with wild-type TP53, whereas it exhibited a better survival outcome in the cases with TP53 mutations.
The current findings suggest that methylation-associated down-regulation of RGC32 plays an important role in the pathogenesis of NSCLC, particularly in females. However, further studies with a large number of cases are needed to confirm the authors' findings. Cancer 2011. © 2010 American Cancer Society.